Articles tagged with Combination Therapies
Polytherapy significantly improves survival outcomes in women with metastatic breast cancer, reducing all-cause mortality by 38% compared to monotherapy. Regular blood pressure medicine adherence also increases survival, especially among Black and Hispanic patients.
The PATINA trial demonstrates a significant progression-free survival benefit with palbociclib in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer. The study showed a median progression-free survival of 44.3 months, compared to 29.1 months in the control arm.
ISM0676 demonstrates excellent metabolic stability, superior efficacy at low doses, and a favorable safety profile, leading to significant body weight reduction and improved body composition. The compound's synergistic efficacy with Semaglutide supports its further clinical development as an obesity treatment.
The American College of Chest Physicians released a new clinical guideline on biologic management in severe asthma. The guideline provides evidence-based recommendations for selecting biologics for different patient populations, considering factors such as baseline oral corticosteroid use and comorbid conditions.
Combocat integrates miniaturized drug dispensing with machine learning to efficiently uncover promising drug combinations. The platform's capabilities were published in Nature Communications, demonstrating its potential for scaling up drug combination screening.
The addition of tucatinib to first-line maintenance therapy with trastuzumab and pertuzumab delayed disease progression in HER2-positive metastatic breast cancer patients, particularly those with brain metastasis. This delay allowed for prolonged time off chemotherapy and maintained disease control.
A new study shows that adding epcoritamab to standard second-line therapy significantly improves follicular lymphoma outcomes, including a nearly 80% reduction in risk of death or disease progression. The treatment was also found to be effective for patients who received it on an outpatient basis.
The ESMO Immuno-Oncology Congress 2025 will discuss key developments in immuno-oncology, including combined approaches, AI in cancer therapy, and innovative strategies across various cancers. The congress aims to advance the field of immunotherapy and improve patient outcomes.
The American Society for Radiation Oncology (ASTRO) has published its first clinical guideline on radiation therapy for gastric cancer. The guidelines provide evidence-based recommendations for the role of radiation therapy in multidisciplinary care, including patient selection, integration with systemic therapy and treatment delivery.
A clinical trial led by the University of Oklahoma Health Stephenson Cancer Center has shown promising results with a new drug combination targeting metastatic colorectal cancer in patients with ATM-deficient tumors. The treatment, combining alnodesertib and irinotecan, showed substantial reductions in cancer size in these patients.
Researchers found a targeted immunotherapy regimen yielded promising survival outcomes for patients with B-cell ALL, outperforming historical results. The treatment was well-tolerated, with more than half completing the full course of therapy, and responded similarly in patients with complex medical histories.
Researchers at the University of Oregon have discovered a new treatment approach using a two-drug combination that is 10,000 times more effective than single-drug antibiotics in killing bacterial cells in lab tests. This promising method could help shorten treatment time and reduce toxicity in patients with chronic wound infections.
Researchers at the University of Navarra have developed FLIP-HEDOS, a model that simulates how much radiation blood absorbs during cancer treatment. The study highlights the importance of protecting blood from radiation, which can impair immune function and lead to hematologic toxicity.
Researchers are developing an AI imaging approach to distinguish between tumor progression and treatment effects in glioblastoma patients, promising to improve care and outcomes. The AI approach has already shown accuracy rates of up to 74% in initial testing.
A study by Zhejiang University reveals how IL-6 reprograms PD-L1 expression in colorectal cancer stem cells, driving immunosuppressive effects. Dual-target therapy combining PI3K and STAT3 inhibitors shows promise in overcoming immunotherapy resistance.
A new drug pairing of Theobromine and Arainosine has been developed to target the influenza virus's ion channel, effectively blocking its replication and spread. This breakthrough combo outperforms Tamiflu in fighting a range of flu strains, including drug-resistant versions.
A study published in Nature Medicine reports final results of a Phase 3 trial showing pembrolizumab plus axitinib offers longer overall and progression-free survival compared to sunitinib for advanced kidney cancer patients. The treatment combination has been linked to higher objective response rates.
The BRACELET-1 trial demonstrated a 20% objective response rate and 12.1-month progression-free survival for patients with unresectable HR+ HER2- tumors, suggesting that adding pelareorep to paclitaxel chemotherapy warrants further investigation in metastatic breast cancer.
Researchers have discovered that TAF2 plays a pivotal role in the growth of liver cancer and can help promote tumor formation. The study's findings suggest that targeting TAF2 could lead to more effective treatments for liver cancer.
Researchers at the University of Chicago Medicine discovered a new phenomenon where high doses of radiation cause growth in existing metastatic tumors. The 'badscopal effect' is attributed to increased production of amphiregulin, which weakens the immune system and makes cancer cells more resistant.
Researchers identified platelets, C-reactive protein, and chromogranin A as markers that can predict the failure of hormone-sensitive prostate cancer treatment. The study also found that miR-375 expression and lymphocyte-to-monocyte ratio are negative predictors for therapy failure in castration-resistant prostate cancer patients.
A Phase II trial found durable antitumor activity in patients with BRCA1/2 mutations treated with olaparib and pembrolizumab, with 8.3% complete response rate
Researchers at MD Anderson Cancer Center present promising results from clinical trials in three minisymposia abstracts. The studies explore personalized vaccine combination therapy for colorectal cancer, radiotherapy to avoid toxicities of systemic treatments for kidney cancer, and engineered exosomes to silence mutant KRAS in pancrea...
A Phase 3 clinical trial has shown that a combination of sotorasib and panitumumab significantly improves progression-free survival in patients with KRAS G12C metastatic colorectal cancer. The study found improved overall survival rates, with the high-dose sotorasib group experiencing a 30% prolongation compared to standard care.
Researchers found basal cell carcinomas (BCCs) have an immune-excluded phenotype with minimal HLA-I expression, even in early development. A stem-like quiescent program suppressed APM genes, which could be reversed to enable BCC immunotherapy.
A new combination therapy using cemiplimab and isatuximab has shown promising results in a phase 2 clinical trial for extranodal NK/T-cell lymphoma, with 51% of patients achieving complete response. The study validated genomic biomarkers and a prognostic model developed by the National Cancer Centre Singapore, offering potential for mo...
The National Comprehensive Cancer Network (NCCN) has awarded four early-career oncologists with $150,000 in funding to tackle pressing challenges in cancer care. The recipients will support studies aiming to improve cancer outcomes through molecular residual disease-guided adjuvant therapy and electronic symptom monitoring.
A meta-analysis of 14 studies reveals that combination lipid-lowering therapy using statins and ezetimibe significantly lowers LDL cholesterol levels and diminishes cardiovascular risks. Early integration of this approach in treatment protocols can substantially curtail mortality and CVD events.
A new editorial highlights a growing concern in cancer care: radiotherapy may leave behind residual disease that can lead to worse long-term outcomes. Studies have shown that patients with residual disease are more likely to experience cancer recurrence and shorter survival, emphasizing the need for regular biopsy-based tests.
Researchers at MD Anderson have made significant breakthroughs in understanding pancreatic cancer's evolutionary process and developing new treatment strategies. They also discovered that surgical resection can enhance antitumor response in patients receiving immune checkpoint therapy for advanced kidney cancer.
Scientists at VCU Massey Comprehensive Cancer Center have discovered a powerful combination therapy that leverages sotorasib and FGTI-2734 to tackle drug resistance in lung cancer. The treatment targets the KRAS G12C mutation, which is responsible for about 14% of non-small cell lung cancers.
Recent advancements in gene sequencing identify distinct genetic landscapes for LUAD and LUSC, influencing treatment strategies. Targeted therapies show promise for specific molecular profiles, while immunotherapy outcomes vary between subtypes.
Groundbreaking research from the CLEAR study reveals that greater tumor shrinkage improves survival outcomes for patients with advanced renal cell carcinoma. The lenvatinib and pembrolizumab combination regimen demonstrates significant long-term benefits, including enhanced effectiveness of subsequent treatments.
A new study reveals that microglia can be reprogrammed from a tumor-promoting state to one that strengthens antitumor responses, reducing brain metastases growth and enhancing immunotherapy responses. Researchers identified a key signaling pathway that, when blocked, reverses the protumoral function of microglia.
A recent study led by Heike Bischoff-Ferrari found that taking omega-3 fatty acids slowed down biological aging across several epigenetic clocks by up to four months. The combination of omega-3, vitamin D, and strength training proved to be even more effective in slowing down the biological aging process.
Researchers developed a novel microscopy technique to study metabolic changes in individual cancer cells at the single-cell level. They found that radiation treatment caused significant metabolic shifts in head and neck squamous cell carcinoma cells, particularly through the activation of HIF-1α.
Researchers developed a computer model called MANAscore to identify tumor-fighting immune cells in lung cancer patients treated with immune checkpoint inhibitors. The three-gene model helped find differences associated with patient response to immunotherapy, including the presence of stem-like memory T cells.
A researcher at the Medical University of South Carolina is developing a new approach to boost the immune system's ability to detect and kill kidney tumors. By targeting mitochondrial DNA, he aims to reactivate the immune system to recognize and target cancer cells more effectively.
Researchers discovered a novel platinum complex that targets androgen receptor signaling, inhibiting cell growth and survival in prostate cancer cells. The complex, 5-H-Y, showed stronger cytotoxic effects than cisplatin with minimal toxicity, offering a promising approach to treating advanced prostate cancer.
Researchers at the University of Alabama at Birmingham have identified HIF1α as a key regulator that induces cancer-killing capacity in T cells under hypoxic conditions. In this study, they found that HIF1α-glycolysis is indispensable for IFN-γ induction in hypoxic T cells.
Fogarty's research aims to monitor language function and recovery in post-stroke patients using DOT. She hopes to establish the feasibility of brain-computer interfaces to restore inter-personal communication for post-stroke patients.
Researchers at Chung-Ang University have identified a crucial role for specific tRNA fragments in cancer progression, revealing their ability to regulate gene expression and influence tumor growth. The study suggests that these fragments could serve as biomarkers for early-stage cancer detection and targets for therapeutic interventions.
Dr. Aditya Bardia's appointment as Editor-in-Chief of Breast Cancer Research and Treatment reflects his expertise in targeted therapies and innovative research. He aims to foster innovation and disseminate knowledge benefiting patients and the scientific community through this journal.
The partnership integrates Answer ALS’s Neuromine Data Portal with the AD Data Initiative's AD Workbench, providing a unified platform for data sharing and analysis. This collaboration enables integrative analysis of ALS and Alzheimer’s data, streamlining efforts and enhancing research impact.
The landmark review charts the transformation of pituitary tumor treatment from early hormone regulation experiments to modern precision therapies. Key findings include significant advances in prolactinoma and acromegaly treatments, as well as emerging areas for research like receptor modulators and immunotherapy.
A new study from Uganda documents partial resistance to artemisinin in 11 out of 100 African children with severe malaria, suggesting a growing concern for the efficacy of lifesaving malaria treatments. The study also reveals that 10 patients who were thought to have been cured suffered repeat malaria attacks within 28 days.
Researchers at MD Anderson Cancer Center present promising new treatments, including a gastric cancer therapy using T cell antigen coupler technology. Additionally, COVID-19 mRNA vaccines are shown to improve responses to immune checkpoint inhibitors in patients with non-small cell lung and melanoma cancers.
The ECOG-ACRIN Cancer Research Group and PrECOG, LLC will present several abstracts at the 66th American Society of Hematology Meeting & Exposition. Promising results from a phase 2 study in acute myeloid leukemia and new data from the practice-changing E1910 phase 3 trial show improved outcomes for patients with B-cell acute lymphobla...
A new study introduces a multi-omics-based molecular classification of gastrointestinal stromal tumors, categorizing them into four distinct subtypes. The findings identify key genetic signatures and tumor suppressor genes that influence treatment response, providing a roadmap for personalized therapy strategies.
A four-year study funded by a $2.5 million grant will investigate the impact of spinal cord transcutaneous stimulation combined with gait training on motor recovery in individuals with traumatic brain injury. The research aims to improve clinical treatment strategies and decision-making for improved gait and functional recovery.
A new study led by CAMH shows that a combination of therapies can slow cognitive decline in older adults with conditions increasing the risk of dementia. Participants receiving Cognitive Remediation plus transcranial direct current stimulation experienced slower cognitive decline compared to those receiving a control intervention.
Two UCF cancer researchers, Alicja Copik and Debbie Altomare, have received $100,000 grants from the Florida Breast Cancer Foundation to develop new treatments for breast cancer. They focus on enhancing natural killer cells to fight cancer and harnessing the body's immune system to create new therapies.
Researchers explore immune activation and tumor-promoting transcription factor FOXM1's role in CDK4/6-MEK resistance. They suggest targeting the oncogenic network of CDK4/6, MEK, PD-L1, and FOXM1 as future treatment options for MPNST patients.
Researchers developed a mathematical model predicting enhanced survival outcomes for NSCLC patients with novel treatment combinations. The model neutralizes the negative effects of miR-155, boosting standard-of-care treatments like cisplatin and immune checkpoint inhibitors.
The integration of artificial intelligence in intratumoral immunotherapy can refine diagnoses, guide interventions, predict treatment responses, and adapt therapeutic strategies. This enables the enhancement of patient outcomes, including improved survival rates and quality of life.
Recent years have seen therapeutic advances in kidney cancer due to deeper understanding of the disease's biology, with improved treatments and early detection contributing to decreased deaths. Cigarette smoking and being overweight remain major risk factors for kidney cancer.
The study compared FDG-PET/CT and CT for evaluating treatment response in unresectable malignant pleural mesothelioma patients. The results showed that both imaging modalities provided accurate findings for tumor response evaluation, with high concordance between the two methods.
A special issue of WORK Journal explores the importance of designing healthy workplaces that address musculoskeletal conditions, burnout, and chronic pain. The issue highlights the need for an interdisciplinary approach integrating medical, psychological, and occupational therapies to prevent work-related illness and injury.
Researchers uncover the importance of kainate receptors in enabling synaptic plasticity and transmission in the cerebellum. The study's findings have significant implications for understanding neurological disorders and developing new treatments.
Researchers at the University of Zurich have discovered a factor secreted by tumor cells that impeds the effectiveness of therapies. The POSTN gene plays an important role in resistant tumors and triggers resistance through its interaction with immune cells, particularly macrophages.